Roca Therapeutics completes seed funding round
Roca Therapeutics
A united team revolutionizing therapy to bring patients a new vision of life.
Roca Therapeutics has closed its seed funding round, led by 3B Future Health Fund I & II and SATT Sud-Est .
The seed round will allow the company to advance development of its lead clinical candidate RCT001 for metastatic Uveal Melanoma, which is expecting to be IND/CTA ready by mid-2023, and to allow us to expand the company’s portfolio of assets by securing a second clinical candidate?against Neovascular Glaucoma associated to Uveal melanoma.?
Uveal melanoma is a rare, deadly disease with a serious unmet therapeutic need. Roca is pursuing a innovative, small molecule therapeutic designed to address dedicated pathobiological mechanisms recently linked to indications such as Uveal melanoma. Read more here.
Check out what our Co-founder and CEO, Maeva Dufies , had to say about this important milestone for Roca Therapeutics.?
Co-founder & Managing Director at Leads To Development
2 年Great news, congratulations!
MATWIN CEO - OncoSTART ccordination
2 年Congrats Maeva & the Roca Therapeutics team ??
Very important achievement for Roca Therapeutics